Sigmoid is developing a number of products of its own, each incorporating the Companys LEDDS® and SmPill® technologies. The three most advanced projects are novel formulations being developed for indications in gastro-intestinal disease, transplantation and neuro-degeneration.
In establishing its in-house pipeline of development stage products, Sigmoid is drawing on positive clinical proof-of-concept studies conducted with a marketed hydrophobic peptide drug. These studies demonstrate very significantly enhanced and accelerated drug absorption and have provided the basis for expanding the companys activities.
Note: This page is being updated. Please visit again soon